Race and institutional factors play an important role in pharmacogenomic trial participation
Cancer therapy has evolved from a "one-size-fits-all" type of treatment plan to a personalized approach based on a patient's type of cancer, the protein and genetic markers found in their tumors and their response to therapy. ...
Jul 28, 2015
0
5